| Description | Miltefosine (HePC) is the treatment of visceral and cutaneous leishmaniasis drug , and is proceeding clinical trials for this in several countries. Several medical agents produce some potency against visceral or cutaneous leishmaniasis, however a 2005 survey concluded that miltefosine is the only effective oral treatment for both forms of leishmaniasis. |
| Cell experiments | 2 × 105 PEL cells are treated with the therapeutic compounds at the indicated doses or with appropriate vehicle as a negative control. Cells are followed for 96 hours, and cell viability is determined by trypan blue exclusion performed in quadruplicate. (Only for Reference) |
| Target activity | PKC:7 μM |
| Synonyms | HePC, 米替福新, Hexadecyl phosphocholine |
| molecular weight | 407.57 |
| Molecular formula | C21H46NO4P |
| CAS | 58066-85-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: 10 mM DMSO: Insoluble |
| References | 1. Uberall F, et al. Y Res, 1991, 51(3), 807-812. 2. Chugh P, et al. Retrovirology, 2008, 5, 11. 3. Ruiter GA, et al. Anticancer Drugs, 2003, 14(2), 167-173. |